Zhang Jian, Zhang Xuena, Wang Hui, Zhou Haibin, Tian Tian, Wu Anshi
Department of Anesthesiology, Beijing Chaoyang Hospital of Capital Medical University, Beijing, China.
Department of Anesthesiology, Ji Shui Tan Hospital and Fourth Medical College of Peking University, Beijing, China.
PLoS One. 2017 Aug 22;12(8):e0183154. doi: 10.1371/journal.pone.0183154. eCollection 2017.
Dexmedetomidine, a highly selective α2-adrenoceptor agonist, has been investigated for anti-shivering effects in some trials. This current meta-analysis was conducted to evaluate the effectiveness of dexmedetomidine as a neuraxial adjuvant in preventing perioperative shivering.
This systematic review and meta-analysis was registered in PROSPERO [www.crd.york.ac.uk/PROSPERO] with the unique identification number CRD42017055991. The electronic databases PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) were searched to select high-quality randomized controlled trials (RCTs) that evaluated the anti-shivering efficacy for neuraxial application dexmedetomidine as local anesthetic adjuvant. Effects were summarized using pooled risk ratios (RRs), weighed mean differences (MDs), or standardized mean differences (SMDs) and corresponding 95% confidence intervals (Cls) with random effect model. Heterogeneity assessment, sensitivity analysis, and publication bias were performed. The primary outcome was perioperative shivering.
A total of 1760 patients from 24 studies were included in this meta-analysis. Compared with the placebo, dexmedetomidine reduced the incidence of perioperative shivering (RR: 0.34; 95% Cl: 0.21 to 0.55; P < 0.00001), with a maximum effective dose of 5μg via subarachnoid space injection (RR: 0.55; 95% CI: 0.32 to 0.92; P = 0.02), especially in cesarean section (RR: 0.20; 95% CI: 0.09 to 0.45; P = 0.0001). Dexmedetomidine also could improve the characteristics of the block, with an increase only in the incidence of bradycardia (RR: 2.11; 95% CI: 1.23 to 3.60; P = 0.006). No significant difference could be found compared dexmedetomidine with other adjuvants, except morphine.
This meta-analysis shows that dexmedetomidine as a neuraxial adjuvant had statistically significant efficacy on prevention of perioperative shivering. Moreover, dexmedetomidine could improve the characteristics of the block. However, the potential induction of bradycardia should be taken seriously.
右美托咪定是一种高度选择性的α2肾上腺素能受体激动剂,在一些试验中已对其抗寒战作用进行了研究。本荟萃分析旨在评估右美托咪定作为神经轴索辅助用药预防围手术期寒战的有效性。
本荟萃分析共纳入来自24项研究的1760例患者。与安慰剂相比,右美托咪定降低了围手术期寒战的发生率(RR:0.34;95%CI:0.21至0.55;P<0.00001),蛛网膜下腔注射的最大有效剂量为5μg(RR:0.55;95%CI:0.32至0.92;P=0.02),尤其在剖宫产中(RR:0.20;95%CI:0.09至0.45;P=0.0001)。右美托咪定还可改善阻滞特征,仅心动过缓发生率增加(RR:2.11;95%CI:1.23至3.60;P=0.006)。与其他辅助用药相比,除吗啡外,右美托咪定未发现显著差异。
本荟萃分析表明,右美托咪定作为神经轴索辅助用药在预防围手术期寒战方面具有统计学显著疗效。此外,右美托咪定可改善阻滞特征。然而,应重视其潜在的心动过缓诱导作用。